UNSPSC 51385003: Zomepirac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 822G987U9J, chemically known as 5-(4-chlorobenzoyl)-1,4-dimethyl-1h-pyrrole-2-acetic acid but generally known as zomepirac, which bears US NIH Compound Identifier 5733. European Medicines Agency schedules Zomepirac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00185MIG.

UNSPSC 51385003 Zomepirac is a Commodity code for a specific nonsteroidal anti-inflammatory drug; however, recent state and local solicitations tagged with this code show no activity seeking zomepirac itself. Instead, the opportunities center on naloxone procurement, direct-to-manufacturer prescription fulfillment models, and generic multi-source pharmaceuticals distributed through established wholesaler networks. The code shows a mismatch between its nominal pharmaceutical scope and the actual work being bought under it in the state and local market.

The most concrete recent opportunity is Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries required to the county community health building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, indicating early-stage market research rather than a committed procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products, requiring products to be available by May 15, 2026 and contracts to be effective July 1, 2026, with pricing weighted at 75 percent of the evaluation and a two-year initial term. Activity under this code spans county health agencies, state health and human services commissions, and multistate cooperative purchasing consortia, with representation in Florida, Texas, and Minnesota.